← Compound index
COMPOUND RECORD / PROSTATEKS

ProstateksПростатекс

Source linked
Research profile Explore published studies, research topics and source-specific findings below.
01 / OVERVIEW

What is it?

Prostateks is a Geropharm rectal suppository containing prostate extract, standardized to water-soluble peptides. It is distinct from Prostateks Plus, which also contains tamsulosin, and from synthetic Prostamax (KEDP).

Identity / background source ↗

Organ-derived peptide research: clinical findings and lineage ↗

Research context

Geropharm’s prostate-extract suppository preparation. A postoperative comparative study evaluated it alongside tamsulosin after prostate surgery. Prostatilen and synthetic Prostamax are related research entries, not interchangeable products.

Selected study findings

human comparative · 2022

Study of this preparation · Indexed abstract; full methods not assessed

127 men after bipolar prostate resection: adjunctive Prostateks 60, tamsulosin-only comparison 67

Urinary symptom, quality-of-life and urine-flow measures improved in both postoperative groups. The Prostateks adjunct group reported larger improvements at one and three months.

Limit: Randomization and blinding are not established in the abstract. Surgery and tamsulosin are co-interventions. The discussion’s comparison with another branded product is not a randomized head-to-head equivalence trial.

Prostate extract after transurethral resection for benign prostatic hyperplasia ↗

Selected findings, not a systematic review or a treatment recommendation. Combination and related-preparation results cannot be attributed to this compound alone. See each source for access status and remaining limitations.

Compound class
Tissue-derived polypeptide preparation
Research collection
Peptide bioregulation · editorial grouping
Research institutions
No institutional affiliation recorded
Source review
Review dates and the material assessed are listed with each publication below.
02 / EVIDENCE DIMENSIONS

Evidence assessment

Human research
—127-patient postoperative comparison with an adjunctive treatment group
Study methods
—Original findings separated from registry records and related-product research
Independent replication
—Independent confirmation not established by these linked records
Source access
—Source-specific review scopes accompany each record
Safety evidence
—Preparation-specific safety data are required; related products cannot substitute

These fields describe different aspects of the evidence. A missing record does not mean that no research exists.

Research context, history and detailed findings
EVIDENCE REVIEW / 6 OCTOBER 2026

Outstanding review questions

Check full allocation, comparator, prespecified outcomes, effect estimates, harms and shared-cohort reporting before drawing a clinical conclusion.

Human reports are linked; their presence does not establish effectiveness. Publication records can share participants. Source counts are not trial counts.

View the collection-wide research audit ↗
PEPTIDE RESEARCH / OCT 2026

Related preparations and evidence

Evidence belongs to the preparation actually studied. A tissue extract and a synthetic peptide can belong to the same research tradition without having equivalent effects or safety.

Prostate: the molecular link

Prostatilen → Prostamax (adjacent short-peptide program)

Tissue-level research association only in this collection; direct molecular derivation of Prostamax from the clinical Prostatilen formulation has not been established.

Clinical evidence and limitations

Historical Prostatilen reports and a 127-patient Prostateks postoperative comparison are linked separately.

Do not assign the Prostatilen cohorts to Prostamax or treat uncontrolled improvement as proof of efficacy.

Related preparations

Some references concern related extracts, reviews or molecular identification rather than direct studies of this compound.

Explore the full bioregulator collection ↗

View this preparation in the Khavinson evidence map ↗

03 / SOURCE RECORDS

Linked sources

Explore the research map and unresolved leads ↗

2022 · Prostate extract after transurethral resection for benign prostatic hyperplasia
2022Human comparative studyEnglish abstract

Prostate extract after transurethral resection for benign prostatic hyperplasia

V. N. Pavlov, A. A. Kazikhinurov, R. A. Kazikhinurov, S. Sh. Sabirzyanov, Yu. D. Saleeva, K. A. Kazikhinurova · Urologiia. 2022;(6):42–46.

Urinary symptom, quality-of-life and urine-flow measures improved in both postoperative groups. The Prostateks adjunct group reported larger improvements at one and three months.

Population / setting
127 men after bipolar prostate resection: adjunctive Prostateks 60, tamsulosin-only comparison 67
What was checked
Publisher English abstract checked; full paper not appraised.
Limitations & review scope
  • Randomization and blinding are not established in the abstract. Surgery and tamsulosin are co-interventions.
  • The discussion’s comparison with another branded product is not a randomized head-to-head equivalence trial.

Source checked 2026-10-07. See the review scope above for the material assessed.

Read the source ↗
Browse bibliography & PDFs ↗